Drugmakers haven’t been shy this week about sharing their views on drug pricing. Thing is, they don’t all agree.

AbbVie and its development partners have big plans for the upcoming American Society of Hematology (ASH) meeting that starts Dec. 3.

In this week's FiercePharmaAsia wrap-up, GSK China has a new leader, Japan's Opdivo price cut raises concerns in the country's regulatory…

As new flu vaccine technology emerges in the coming years, smaller players will have a shot at stealing market share.

While only one president has left an FDA Commissioner in place when taking office, supporters of Commissioner Dr. Robert Califf are hopeful history will repeat…

After an initial rejection, Glaxo’s first-in-class severe asthma treatment Nucala has passed the tough examination of England’s cost watchdogs.

Merck’s Keytruda has nabbed its second FDA priority review tag of the week—and it’s one that’ll help it gain ground Bristol-Myers Squibb's Opdivo.

Allergan CEO Brent Saunders is urging his pharma peers to ready for drug price reforms under U.S. President-elect Donald Trump.